The company’s core platform, Elix Discovery, integrates compound prediction, molecular design, and active learning tools in a single environment tailored for drug developers. Its models support early-stage discovery by predicting drug-like properties, generating new molecular structures, and optimizing candidate selection. In July 2025, Elix introduced a federated learning framework to train AI models across proprietary data from multiple pharmaceutical companies without direct data sharing—aimed at expanding the scale and accuracy of its discovery platform.

Elix’s platforms are now being adopted by global pharmaceutical partners. Notably, Eisai and KYORIN Pharmaceutical announced adoption of Elix Discovery in mid-2025, highlighting growing traction among major drugmakers.